CLIA Kit for Ischemia Modified Albumin (IMA) Homo sapiens (Human) Competition CLIA

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • CLIA Kit for Ischemia Modified Albumin (IMA) Packages (Simulation)
  • CLIA Kit for Ischemia Modified Albumin (IMA) Packages (Simulation)
  • CLIA Kit for Ischemia Modified Albumin (IMA) Results demonstration
  • CCA825Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Ischemia Modified Albumin (IMA) and the recovery rates were calculated by comparing the measured value to the expected amount of Ischemia Modified Albumin (IMA) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-104 99
EDTA plasma(n=5) 91-102 99
heparin plasma(n=5) 90-98 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Ischemia Modified Albumin (IMA) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Ischemia Modified Albumin (IMA) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Ischemia Modified Albumin (IMA) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 89-99% 85-93% 95-102% 85-101%
EDTA plasma(n=5) 87-94% 99-105% 85-95% 90-101%
heparin plasma(n=5) 94-102% 83-104% 98-105% 87-95%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1 Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Reagent Diluent 1×300µL Substrate B 1×2mL
Substrate A 1×10mL Instruction manual 1
Wash Buffer (30 × concentrate) 1×20mL

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
7. Read RLU value immediately.

CLIA Kit for Ischemia Modified Albumin (IMA)

Test principle

The microplate provided in this kit has been pre-coated with a monoclonal antibody specific to Ischemia Modified Albumin (IMA). A competitive inhibition reaction is launched between biotin labeled Ischemia Modified Albumin (IMA) and unlabeled Ischemia Modified Albumin (IMA) (Standards or samples) with the pre-coated antibody specific to Ischemia Modified Albumin (IMA). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Ischemia Modified Albumin (IMA) in the sample. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is reverse proportional to the Ischemia Modified Albumin (IMA) level in the sample or standard.

Citations

  • The role of protein oxidation and DNA damage in elderly hypertensionPubMed: 26487663
  • The impact of protein oxidation on sustained and white coat hypertensionpubmed:27684518
  • Investigation of serum ischemia-modified albumin levels in coronary artery disease patients
  • Effects of Different Heart Positions During Off-pump Coronary Artery Bypass Surgery on Serum Ischemia Modified Albumin Level and Cardiac Output

Recommend products